Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of …
Background The safety and efficacy of ocrelizumab in primary progressive multiple sclerosis
were shown in the phase 3 ORATORIO trial. In this study, we assessed the effects of …
were shown in the phase 3 ORATORIO trial. In this study, we assessed the effects of …
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
[HTML][HTML] Ocrelizumab: a review in multiple sclerosis
YN Lamb - Drugs, 2022 - Springer
Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
PS Sorensen, M Blinkenberg - Therapeutic advances in …, 2016 - journals.sagepub.com
B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and …
Background Ocrelizumab is an infusible humanized monoclonal antibody that selectively
depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the …
depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the …
Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis
Background and Objectives To report safety of ocrelizumab (OCR) up to 7 years in patients
with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) …
with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) …
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
Background No evidence of disease activity (NEDA; defined as no 12-week confirmed
disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 …
disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 …
[HTML][HTML] Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
C Rodriguez-Mogeda, ZYGJ van Lierop… - Journal of …, 2023 - Springer
Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …
Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis
Background and Objectives Ocrelizumab improved clinical and MRI measures of disease
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in …
Importance Accumulation of disability in multiple sclerosis may occur as relapse-associated
worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA …
worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA …